US Stem Cell Inc (USRM)

[Investaholic33]

I don't believe BioHeart is shifting any resources away from the FDA trials. If anything, they're putting more into it, considering the continuation of trials and the addition of new FDA trials. They just now have other aspects and operations of the business they can send out PRs about.

However, I do believe as a business decision, it is incredibly wise to focus on building up within the "medical tourism" community, and very positive for BHRT share holders.

I have multiple reasons for that belief, all theory, of course.

My main reasoning why it's so important:
Hypothetically, let's say FDA approval takes a very long time, and it's not going to happen any time soon.
By effectively establishing themselves throughout the world as a viable option for effective and safe medical treatment, BioHeart can bring in a substantial level of revenue, that will presumably trickle to the equity of shareholders.

According to the World Travel & Tourism Council (WTTC), medical tourism contributed 9 percent of global GDP (more than US$6 Trillion)!

That was 2011, and the sector is only growing. BioHeart can gain significant revenue by establishing themselves as a viable option for medical tourism.

Another reason is brand strength. BioHeart is effectively getting their name out into the international medical community. Better odds of patients seeking their specific treatments.

This will also play a key factor when BioHeart does get FDA approval. If they're already providing their services effectively throughout the world, factor in what affect FDA approval would have.
They would be already established and performing treatments in a given region. Now add the trust of successful FDA trials and the rigorous FDA approval process. Patients in and around the region would be even more willing and trusting to under go BioHeart's treatment... and that trust can certainly be worth money, in that BioHeart could easily charge a little more for the same service (not a whole lot more, but definitely still more).